Company intelligence / Profile preview

1Cell.Ai

Foster City, California, United Statesonecelldx.com ↗

Ownership: Private
Development stage: Commercial

Overview

1Cell.Ai has launched OncoIncytes, a comprehensive multi-modal cancer diagnostic panel that integrates ctDNA, CTCs, RNA transcriptomics, and proteomics data. Their 1080 gene panel was validated against Illumina's TSO 500 and FDA-cleared PGDx panel with 100% concordance[1][2].

Therapeutic areas: Oncology
Modalities: DiagnosticsAI-powered analytics
Industry: Molecular Diagnostics

Partnerships

BioSkryb Genomics

Beyond the preview

Go deeper on 1Cell.Ai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1Cell.Ai.

Explore the full profile